Oncología clínica

Bademci R., Bollo J., Ramon y Cajal T., Martinez M.C., Hernandez M.P., Targarona E.M. (2020) Presentation and Follow-up of Familial Adenomatous Polyposis: Differences Between APC and MUTYH Mutations Presentación y seguimiento de poliposis adenomatosa familiar (PAF): diferencias entre las mutaciones APC y MUTYH. CIR ESPAN, 98 (8), 465-471.

IF: 1,6530

Balana C., Vaz M.A., Manuel Sepulveda J., Mesia C., Del Barco S., Pineda E., Munoz-Langa J., Estival A., de Las Penas R., Fuster J., Girones R., Navarro L.M., Gil-Gil M., Alonso M., Herrero A., Peralta S., Olier C., Perez-Segura P., Covela M., Martinez-Garcia M., Berrocal A., Gallego O., Luque R., Perez-Martin F.J., Esteve A., Munne N., Domenech M., Villa S., Sanz C., Carrato C. (2020) A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01). NEURO-ONCOLOGY, 22 (12), 1851-1861.

IF: 12,3000

Brausi M., Hoskin P., Andritsch E., Banks I., Beishon M., Boyle H., Colecchia M., Delgado-Bolton R., Hockel M., Leonard K., Lovey J., Maroto P., Mastris K., Medeiros R., Naredi P., Oyen R., de Reijke T., Selby P., Saarto T., Valdagni R., Costa A., Poortmans P. (2020) ECCO Essential Requirements for Quality Cancer Care: Prostate cancer. CRIT REV ONCOL HEMAT, 148 (), -.

IF: 6,3120

Carrato C., Alameda F., Esteve-Codina A., Pineda E., Arpi O., Martinez-Garcia M., Mallo M., Gut M., Lopez-Martos R., Barco S.D., Ribalta T., Capellades J., Puig J., Gallego O., Mesia C., Munoz-Marmol A.Ma., Archilla I., Arumi M., Blanc J.M., Bellosillo B., Menendez S., Esteve A., Bague S., Hernandez A., Craven-Bartle J., Fuentes R., Vidal N., Aldecoa I., de la Iglesia N., Balana C. (2020) Glioblastoma TCGA mesenchymal and IGS 23 tumors are identifiable by ihc and have an immune-phenotype indicating a potential benefit from immunotherapy. CLIN CANCER RES, 26 (24), 6600-6609.

IF: 12,5310

Chowdhury S., Bjartell A., Lumen N., Maroto P., Paiss T., Gomez-Veiga F., Birtle A., Kramer G., Kalinka E., Spaeth D., Feyerabend S., Matveev V., Lefresne F., Lukac M., Wapenaar R., Costa L. (2020) Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry. TARGET ONCOL, 15 (3), 301-315.

IF: 4,4930

Cotes Sanchis A., Gallego J., Hernandez R., Arrazubi V., Custodio A., Cano J.M., Aguado G., Macias I., Lopez C., Lopez F., Visa L., Garrido M., Martinez Lago N., Fernandez Montes A., Limon M.L., Azkarate A., Pimentel P., Reguera P., Ramchandani A., Cacho J.D., Martin Carnicero A., Granja M., Martin Richard M., Hernandez Perez C., Hurtado A., Serra O., Buxo E., Vidal Tocino R., Jimenez-Fonseca P., Carmona-Bayonas A. (2020) Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry. PLOS ONE, 15 (7 July), e0235848-.

IF: 3,2400

Earl J., Galindo-Pumarino C., Encinas J., Barreto E., Castillo M.E., Pachon V., Ferreiro R., Rodriguez-Garrote M., Gonzalez-Martinez S., Ramon y Cajal T., Diaz L.R., Chirivella-Gonzalez I., Rodriguez M., de Castro E.M., Garcia-Seisdedos D., Munoz G., Rosa J.M.R., Marquez M., Malats N., Carrato A. (2020) A comprehensive analysis of candidate genes in familial pancreatic cancer families reveals a high frequency of potentially pathogenic germline variants. EBIOMEDICINE, 53 (), -.

IF: 8,1430

Etan T., Amir E., Tibau A., Yerushalmi R., Moore A., Shepshelovich D., Goldvaser H. (2020) National comprehensive cancer network recommendations for drugs without US food and drug administration approval in metastatic breast cancer: A cross-sectional study. CANCER TREAT REV, 91 (), -.

IF: 12,1110

Feliu J., Garcia-Carbonero R., Capdevila J., Guasch I., Alonso-Orduna V., Lopez C., Garcia-Alfonso P., Castanon C., Sevilla I., Cerezo L., Conill C., Quintana-Angel B., Sanchez M.E., Ghanem I., Martin-Richard M., Lopez-Gomez M., Leon A., Caro M., Fernandez T., Maurel J. (2020) VITAL phase 2 study: Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02). CANCER MED-US, 9 (3), 1008-1016.

IF: 4,4520

Gafter-Gvili A., Tibau A., Raanani P., Shepshelovich D. (2020) Safety-Related Postmarketing Modifications of Drugs for Hematological Malignancies. ACTA HAEMATOL-BASEL, 143 (1), 73-77.

IF: 2,1950

Gallardo E., Medina J., Sanchez J.C., Viudez A., Grande E., Porras I., Ramon y Cajal T., Trigo J., Iglesias L., Capdevila J. (2020) SEOM clinical guideline thyroid cancer (2019). CLIN TRANSL ONCOL, 22 (2), 223-235.

IF: 3,4050

Garcia-Campelo R., Arrieta O., Massuti B., Rodriguez-Abreu D., Granados A.L.O., Majem M., Vicente D., Lianes P., Bosch-Barrera J., Insa A., Domine M., Reguart N., Guirado M., Sala M.A., Vazquez-Estevez S., Caro R.B., Drozdowskyj A., Verdu A., Karachaliou N., Molina-Vila M.A., Rosell R. (2020) Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL). LUNG CANCER, 150 (), 62-69.

IF: 5,7050

Gomez de Liano Lista A., van Dijk N., de Velasco Oria de Rueda G., Necchi A., Lavaud P., Morales-Barrera R., Alonso Gordoa T., Maroto P., Ravaud A., Duran I., Szabados B., Castellano D., Giannatempo P., Loriot Y., Carles J., Anguera Palacios G., Lefort F., Raggi D., Gross Goupil M., Powles T., Van der Heijden M.S. (2020) Clinical outcome after progressing to frontline and second-line Anti–PD-1/PD-L1 in advanced urothelial cancer[Formula presented]. EUR UROL, 77 (2), 269-276.

IF: 20,0960

Gonzalez-del-Alba A., Arranz J.A., Bellmunt J., Maroto J.P., Fernandez-Calvo O., Valderrama B.P., Gonzalez-Billalabeitia E., Mendez-Vidal M.J., Cassinello J., Romero-Laorden N., Climent M.A., Puente J., Pelaez I., Lazaro-Quintela M., Gallardo E., Suarez C. (2020) Latest progress in molecular biology and treatment in genitourinary tumours. CLIN TRANSL ONCOL, 22 (12), 2175-2195.

IF: 3,4050

Gonzalez-Santiago S., Ramon y Cajal T., Aguirre E., Ales-Martinez J.E., Andres R., Balmana J., Grana B., Herrero A., Llort G., Gonzalez-del-Alba A. (2020) SEOM clinical guidelines in hereditary breast and ovarian cancer (2019). CLIN TRANSL ONCOL, 22 (2), 193-200.

IF: 3,4050

Gridelli C., Ciuleanu T., Domine M., Szczesna A., Bover I., Cobo M., Kentepozidis N., Zarogoulidis K., Kalofonos C., Kazarnowisz A., Korozan M., de las Penas R., Majem M., Chella A., Griesinger F., Bournakis E., Sadjadian P., Kotsakis A., Chinet T., Syrigos K.N., Correale P., Gallou C., Jamet J.-M., Vetsika E.-K., Kosmatopoulos K., Georgoulias V. (2020) Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical trial. BRIT J CANCER, 122 (10), 1461-1466.

IF: 7,6400

Gronchi A., Palmerini E., Quagliuolo V., Martin Broto J., Lopez Pousa A., Grignani G., Brunello A., Blay J.-Y., Tendero O., Diaz Beveridge R., Ferraresi V., Lugowska I., Merlo D.F., Fontana V., Marchesi E., Braglia L., Donati D.M., Palassini E., Bianchi G., Marrari A., Morosi C., Stacchiotti S., Bague S., Coindre J.M., Dei Tos A.P., Picci P., Bruzzi P., Casali P.G. (2020) Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: Final results of a randomized trial from Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) sarcoma groups. J CLIN ONCOL, 38 (19), 2178-2186.

IF: 44,5440

Herbst R.S., Garon E.B., Kim D.-W., Cho B.C., Perez-Gracia J.L., Han J.-Y., Arvis C.D., Majem M., Forster M.D., Monnet I., Novello S., Szalai Z., Gubens M.A., Su W.-C., Ceresoli G.L., Samkari A., Jensen E.H., Lubiniecki G.M., Baas P. (2020) Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1‒positive, advanced non‒small-cell lung cancer in the KEYNOTE-010 study. J CLIN ONCOL, 38 (14), 1580-1591.

IF: 44,5440

Isla D., de Castro J., Garcia-Campelo R., Majem M., Vicente D., Juan-Vidal O., Treatment strategy optimization for patients with non-small-cell lung cancer harboring EGFR mutation: a Delphi consensus (2020) CLIN TRANSL ONCOL.

IF: 3,4050

Laquente B., Macarulla T., Buges C., Martin M., Garcia C., Pericay C., Merino S., Visa L., Martin T., Pedraza M., Carnero B., Guardeno R., Verdaguer H., Mut A., Vilanova D., Garcia A. (2020) Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine practice. BMC PALLIAT CARE, 19 (1), 103-.

IF: 3,2340

Lewis J.H., Gelderblom H., van de Sande M., Stacchiotti S., Healey J.H., Tap W.D., Wagner A.J., Pousa A.L., Druta M., Lin C.-C., Baba H.A., Choi Y., Wang Q., Shuster D.E., Bauer S., Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors (2020) ONCOLOGIST.

IF: 5,5500

Loriot Y., Sternberg C.N., Castellano D., Oosting S.F., Dumez H., Huddart R., Vianna K., Gordoa T.A., Skoneczna I., Fay A.P., Nole F., Massari F., Brasiuniene B., Maroto P., Fear S., Di Nucci F., de Ducla S., Choy E. (2020) Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma. EUR J CANCER, 138 (), 202-211.

IF: 9,1620

Majem M., Garcia-Martinez E., Martinez M., Munoz-Couselo E., Rodriguez-Abreu D., Alvarez R., Arance A., Berrocal A., de la Cruz-Merino L., Lopez-Martin J.A. (2020) SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019). CLIN TRANSL ONCOL, 22 (2), 213-222.

IF: 3,4050

Majem M., Hernandez-Hernandez J., Hernando-Trancho F., Rodriguez de Dios N., Sotoca A., Trujillo-Reyes J.C., Vollmer I., Delgado-Bolton R., Provencio M. (2020) Multidisciplinary consensus statement on the clinical management of patients with stage III non-small cell lung cancer. CLIN TRANSL ONCOL, 22 (1), 21-36.

IF: 3,4050

Martin-Broto J., Hindi N., Lopez-Pousa A., Peinado-Serrano J., Alvarez R., Alvarez-Gonzalez A., Italiano A., Sargos P., Cruz-Jurado J., Isern-Verdum J., Dolado M.C., Rincon-Perez I., Sanchez-Bustos P., Gutierrez A., Romagosa C., Morosi C., Grignani G., Gatti M., Luna P., Alastuey I., Redondo A., Belinchon B., Martinez-Serra J., Sunyach M.-P., Coindre J.-M., Dei Tos A.P., Romero J., Gronchi A., Blay J.-Y., Moura D.S. (2020) Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients with Metastatic Soft-Tissue Sarcomas: A Nonrandomized Phase 1/2 Clinical Trial. JAMA ONCOL, 6 (4), 535-541.

IF: 31,7770

Martin-Broto J., Cruz J., Penel N., Le Cesne A., Hindi N., Luna P., Moura D.S., Bernabeu D., de Alava E., Lopez-Guerrero J.A., Dopazo J., Pena-Chilet M., Gutierrez A., Collini P., Karanian M., Redondo A., Lopez-Pousa A., Grignani G., Diaz-Martin J., Marcilla D., Fernandez-Serra A., Gonzalez-Aguilera C., Casali P.G., Blay J.-Y., Stacchiotti S. (2020) Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial. LANCET ONCOL, 21 (3), 456-466.

IF: 41,3160

Martin-Broto J., Hindi N., Grignani G., Martinez-Trufero J., Redondo A., Valverde C., Stacchiotti S., Lopez-Pousa A., D'Ambrosio L., Gutierrez A., Perez-Vega H., Encinas-Tobajas V., de Alava E., Collini P., Pena-Chilet M., Dopazo J., Carrasco-Garcia I., Lopez-Alvarez M., Moura D.S., Lopez-Martin J.A. (2020) Nivolumab and sunitinib combination in advanced soft tissue sarcomas: A multicenter, single-arm, phase Ib/II trial. J IMMUNOTHER CANCER, 8 (2), -.

IF: 13,7510

Martin-Richard M., Carmona-Bayonas A., Custodio A.B., Gallego J., Jimenez-Fonseca P., Reina J.J., Richart P., Rivera F., Alsina M., Sastre J. (2020) SEOM clinical guideline for the diagnosis and treatment of gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJA) (2019). CLIN TRANSL ONCOL, 22 (2), 236-244.

IF: 3,4050

Molto C., Hwang T.J., Borrell M., Andres M., Gich I., Barnadas A., Amir E., Kesselheim A.S., Tibau A. (2020) Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration. CANCER-AM CANCER SOC, 126 (19), 4390-4399.

IF: 6,8600

Mulet M., Zamora C., Porcel J.M., Nieto J.C., Pajares V., Munoz-Fernandez A.M., Calvo N., Esquerda A., Vidal S. (2020) Platelet factor 4 regulates T cell effector functions in malignant pleural effusions. CANCER LETT, 491 (), 78-86.

IF: 8,6790

Mur P., Garcia-Mulero S., del Valle J., Magraner-Pardo L., Vidal A., Pineda M., Cinnirella G., Martin-Ramos E., Pons T., Lopez-Doriga A., Belhadj S., Feliubadalo L., Munoz-Torres P.M., Navarro M., Grau E., Darder E., Llort G., Sanz J., Ramon y Cajal T., Balmana J., Brunet J., Moreno V., Piulats J.M., Matias-Guiu X., Sanz-Pamplona R., Aligue R., Capella G., Lazaro C., Valle L. (2020) Role of POLE and POLD1 in familial cancer. GENET MED, 22 (12), 2089-2100.

IF: 8,8220

Peters S., Danson S., Hasan B., Dafni U., Reinmuth N., Majem M., Tournoy K.G., Mark M.T., Pless M., Cobo M., Rodriguez-Abreu D., Falchero L., Moran T., Ortega Granados A.L., Monnet I., Mohorcic K., Sureda B.M., Betticher D., Demedts I., Macias J.A., Cuffe S., Luciani A., Sanchez J.G., Curioni-Fontecedro A., Gautschi O., Price G., Coate L., von Moos R., Zielinski C., Provencio M., Menis J., Ruepp B., Pochesci A., Roschitzki-Voser H., Besse B., Rabaglio M., O'Brien M.E.R., Stahel R.A. (2020) A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial. J THORAC ONCOL, 15 (10), 1647-1656.

IF: 15,6090

Pico M.D., Castillejo A., Murcia O., Giner-Calabuig M., Alustiza M., Sanchez A., Moreira L., Pellise M., Castells A., Carrillo-Palau M., Ramon y Cajal T., Gisbert-Beamud A., Llort G., Yague C., Lopez-Fernandez A., Alvarez-Urturi C., Cubiella J., Rivas L., Rodriguez-Alcalde D., Herraiz M., Garau C., Dolz C., Bujanda L., Cid L., Poves C., Garzon M., Salces I., Ponce M., Hernandez-Villalba L., Alenda C., Balaguer F., Soto J.-L., Jover R. (2020) Clinical and Pathological Characterization of Lynch-Like Syndrome. CLIN GASTROENTEROL H, 18 (2), 368-374.e1.

IF: 11,3820

Provencio M., Nadal E., Insa A., Garcia-Campelo M.R., Casal-Rubio J., Domine M., Majem M., Rodriguez-Abreu D., Martinez-Marti A., De Castro Carpeno J., Cobo M., Lopez Vivanco G., Del Barco E., Bernabe Caro R., Vinolas N., Barneto Aranda I., Viteri S., Pereira E., Royuela A., Casarrubios M., Salas Anton C., Parra E.R., Wistuba I., Calvo V., Laza-Briviesca R., Romero A., Massuti B., Cruz-Bermudez A. (2020) Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. LANCET ONCOL, 21 (11), 1413-1422.

IF: 41,3160

Puente J., Anido U., Climent M.A., Gonzalez-Billalabeitia E., Lainez N., Lambea J., Maroto J.P., Mendez-Vidal M.J., Montesa A., Rodriguez A., Zambrana C., Gonzalez-del-Alba A. (2020) Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE. THER ADV MED ONCOL, 12 (), -.

IF: 8,1680

Remon J., Nadal E., Domine M., Ruffinelli J., Garcia Y., Pardo J.C., Lopez R., Cilleruelo A., Garcia-Campelo R., Martin P., Juan O., Gonzalez-Larriba J.L., Provencio M., Olmedo E., Ponce S., Cumplido D., Barenys C., Majem M., Massutti B., Rodriguez-Abreu D., Porta R., Sala M.A., Martinez-Kareaga M., Lianes P., Reguart N. (2020) Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group. LUNG CANCER, 147 (), 83-90.

IF: 5,7050

Riera P., Artigas-Baleri A., Salazar J., Sebio A., Virgili A.C., Arranz M.J., Paez D. (2020) ABCB1 Genetic Variants as Predictors of Irinotecan-Induced Severe Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients. FRONT PHARMACOL, 11 (), -.

IF: 5,8100

Riudavets M., Mosquera J., Garcia-Campelo R., Serra J., Anguera G., Gallardo P., Sullivan I., Barba A., del Carpio L., Barnadas A., Gich I., Majem M. (2020) Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents. FRONT ONCOL, 10 (), -.

IF: 6,2440

Roldan-Romero J.M., Santos M., Lanillos J., Caleiras E., Anguera G., Maroto P., Garcia-Donas J., de Velasco G., Martinez-Montes A.M., Calsina B., Monteagudo M., Leton R., Leandro-Garcia L.J., Montero-Conde C., Cascon A., Robledo M., Rodriguez-Antona C. (2020) Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome. MODERN PATHOL, 33 (12), 2580-2590.

IF: 7,8420

Shepshelovich D., Yahav D., Tibau A., Amir E. (2020) Assessment of frequency and reporting of design changes among clinical drug trials published in influential medical journals. EUR J INTERN MED, 71 (), 45-49.

IF: 4,4870

Vokinger K.N., Hwang T.J., Grischott T., Reichert S., Tibau A., Rosemann T., Kesselheim A.S. (2020) Prices and clinical benefit of cancer drugs in the USA and Europe: a cost–benefit analysis. LANCET ONCOL, 21 (5), 664-670.

IF: 41,3160

Wu Y.-L., Tsuboi M., He J., John T., Grohe C., Majem M., Goldman J.W., Laktionov K., Kim S.-W., Kato T., Vu H.-V., Lu S., Lee K.-Y., Akewanlop C., Yu C.-J., de Marinis F., Bonanno L., Domine M., Shepherd F.A., Zeng L., Hodge R., Atasoy A., Rukazenkov Y., Herbst R.S. (2020) Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. NEW ENGL J MED, 383 (18), 1711-1723.

IF: 91,2450